Trials / Completed
CompletedNCT05214482
A Study of AK112 in Advanced Malignant Tumors
A Phase Ib/II Study of AK112（PD-1 / VEGF Bispecific Antibody） in Combination With AK117（Anti-CD47 Antibody）With or Without Chemotherapy in Advanced Malignant Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117（Anti-CD47 Antibody）with or without chemotherapy in advanced malignant tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK112 | IV infusion,Specified dose on specified days |
| DRUG | AK117 | IV infusion,Specified dose on specified days |
| DRUG | Chemotherapy | IV infusion,Specified dose on specified days |
Timeline
- Start date
- 2022-01-22
- Primary completion
- 2025-11-20
- Completion
- 2025-12-31
- First posted
- 2022-01-28
- Last updated
- 2026-03-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05214482. Inclusion in this directory is not an endorsement.